Manufacturing Issues Shape Follow-On Biologics Debate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturing Issues Shape Follow-On Biologics Debate
Product characterization and production challenges are key issues in developing a pathway for biosimilar therapies.


Pharmaceutical Technology


The ability of modern analytical techniques to ensure that generic or follow-on versions of biotechnology therapies are comparable to innovator products is a central issue in establishing a legal process for bringing these products to market. Generic drug makers, as well as some biotechnology companies, want Congress to authorize the US Food and Drug Administration to approve similar biologics based on an abbreviated testing-and-application system.


Jill Wechsler
The Hatch–Waxman Act established such a process for conventional drugs in 1984, but it does not apply to biologics regulated by the Public Health Service Act. Difficulties in assessing comparability and "sameness" has inhibited FDA from approving follow-on versions of those biologics regulated under the Food, Drug, and Cosmetic Act (FDCA). Now many manufacturers claim they have the science and the skill to document the comparability and safety of large molecules and are pressing to overcome the legal obstacles.

To ensure the safety and efficacy of follow-ons while also protecting markets and preserving research and development incentives, brand manufacturers insist that all follow-on biologics require additional preclinical and clinical testing. Even then, follow-ons might not be interchangeable with brands, a situation that would limit patient access and product sales. The debate is heating up as momentum builds for authorizing follow-on biologics or follow-on proteins (as FDA prefers) as a way to reduce spending on costly biotechnology therapies. Innovator companies want to keep the issue from blocking the speedy reauthorization of the prescription-drug user fee program and may be willing to compromise on a measure addressing biotechnology development and regulation.

The status of the science


In Washington This Month
All sides agree that science should determine the scope of follow-on testing, but they disagree about where the science stands. Generics makers maintain that advances in analytical testing can ensure the comparability and safety of follow-on products. "Our ability to make and characterize protein products and other complex biologics has progressed rapidly in the last few decades," said Ajaz Hussain, vice-president of Sandoz and former FDA official, in testimony before the Senate Health, Education, Labor, and Pensions (HELP) Committee in early March 2007.

Small biotechnology and testing companies, moreover, are creating new technical methods to develop follow-ons. One such method is a protein-characterization platform described by Insmed President Geoffrey Allan at a hearing held by the House Oversight and Government Reform Committee. Seattle-based Cell Therapeutics recently announced plans to use its genetic polymer technology to facilitate follow-on development.

These and other manufacturers believe that comparability protocols provide a model for follow-on development and evaluation. FDA allows innovator firms to use mass spectroscopy and other technologies to demonstrate that significant manufacturing changes—such as product reformulation or a move to a new plant—yield new products that are essentially the same as the original treatment.

In fact, FDA is encouraging manufacturers to adopt sophisticated quality-by-design production techniques that can limit the volume of data and testing needed to document comparability following manufacturing changes. The aim is to spur pharmaceutical companies to make continuous improvements in their manufacturing processes, explained FDA Deputy Commissioner Janet Woodcock at the House hearing.

But she also noted the need for comprehensive information about the structural aspects of a protein, as well as for a full understanding of the product's mode of action, to predict clinical comparability. A new manufacturer would not have all the information about the innovator's intermediate manufacturing steps, Woodcock pointed out, and would bear the burden of demonstrating that a similar therapy from a different company works the same as the reference product.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here